COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease

Evidence from past epidemics and preclinical research suggests that the COVID-19 pandemic may have a long-lasting impact on the pandemic of Parkinson's disease, scientists write in JPD

May 12, 2020 - Amsterdam, NL – Parkinson's disease (PD) is expected to reach over 14 million cases worldwide by 2040. As longevity increases, so does the number of persons living with PD. Writing in the Journal of Parkinson's Disease (JPD), scientists discuss several avenues through which the COVID-19 pandemic might contribute to the expected exponential growth of PD in the coming years, compounding the economic and societal impacts of the disease. More...

May 12, 2020

Passive Immunization May Slow Down SARS-CoV-2 and Boost Immunity in Patients, Buying Time Until Vaccines Are Developed

Using antibodies from recovered patients has been life-saving for other acute infections and should be explored in response to COVID-19, researchers say in the International Journal of Risk & Safety in Medicine

May 12, 2020 - Amsterdam, NL – The worldwide COVID-19 pandemic has infected more than 4 million people and killed close to 280,000.1 Finding a vaccine has become a global public health priority. However, creating a viable vaccine might take a long time; scientists estimate a vaccine may be available in between 12 and 18 months. A potential interim solution reported in the International Journal of Risk & Safety in Medicine may be a passive vaccine, or passive immummization (PI), which can provide instant, short-term fortification against infectious agents. More...

May 12, 2020

New Trial Platform Could Accelerate Finding a Cure for Parkinson’s Disease

Scientists describe the concept of a multi-arm, multi-stage trial for evaluating potential therapies for Parkinson's disease and lessons learned from similar trials in other neurogenerative diseases and cancer in JPD

May 6, 2020 - Amsterdam, NL – Despite 30 years of research, not a single therapy has been found to successfully delay or stop the progression of Parkinson's disease (PD). In the Journal of Parkinson's Disease scientists report on the possibility of using a multi-arm, multi-stage trial platform to evaluate several potential therapies at once, using lessons learned from other diseases. More...

May 6, 2020

New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease

Analysis of participants in the Harvard Biomarkers Study highlights the inverse association between low caffeine consumption and blood urate levels and PD, report scientists in JPD

May 5, 2020 - Amsterdam, NL – Two purines, caffeine and urate, have been associated with a reduced risk of Parkinson's disease (PD) in multiple study groups and populations. Analysis of data from the Harvard Biomarkers Study shows that lower levels of caffeine consumption and lower blood urate are inversely associated with PD, strengthening the links between caffeine intake and urate levels and PD, reports a study in the Journal of Parkinson's Disease (JPD). More...

May 5, 2020